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Abstract. In many tumor types, angiogenesis is the net result 
of pro- and anti-angiogenic mediators and correlated with 
metabolic activity, growth, and degree of malignancy. One of 
the first discovered anti-angiogenic compounds is angiostatin, 
a proteolytic fragment of plasminogen. The requirements for 
in vivo angiostatin generation have not yet been determined. 
We investigated the levels of plasminogen and angiostatin 
by western blotting and of components of the plasminogen 
activator complex by ELISA in cyst fluid derived from benign 
and malignant ovarian tumors. Fluid samples from functional 
ovarian follicles, dermoid cysts and endometriotic lesions 
were evaluated separately. When no or minimal amounts of 
plasminogen were present in the cyst fluids, angiostatin was 
generally absent as well, irrespective of plasminogen activator 
concentrations. When plasminogen was present, the degree 
of conversion of plasminogen to angiostatin was significantly 
correlated with the level of uPA, and, to a lesser extent, to the 
tPA level. However, angiostatin was also found in a number of 
cyst fluid samples with minimal or no plasminogen activators, 
suggesting the involvement of other angiostatin generating 
proteases in these samples. Conversely, no angiostatin was 
observed in a number of cyst fluid samples containing both 
plasminogen and plasminogen activators. The presence of 
an inhibitor of the enzymatic activity of uPA and/or tPA, 
like PAI-1, may explain this finding. Our data show that 
plasminogen activators are clearly involved in in vivo angio-
statin formation in ovarian cysts. Most likely, however, other 
proteases, as well as inhibitors of plasminogen activators, are 
involved as well.
Introduction
All tissues are dependent on angiogenesis for their sustained 
growth. In the case of pathological tissue growth, i.e., in malig-
nant tumors and endometriosis, angiogenesis is also required 
for the formation of metastases and ectopic endometriotic 
lesions, respectively (1,2). Angiogenesis is considered to be the 
result of a net balance between the actions of pro- and anti-
angiogenic factors (3-5). Pro-angiogenic factors include growth 
factors such as vascular endothelial growth factor (VEGF) 
(6,7), proteases (plasminogen activators, matrix metallopro-
teinases or MMPs; (8,9), integrin adhesion molecules (αvβ3, 
αvβ5) (10,11), extracellular matrix components (collagens, 
laminins, proteoglycans) and many others. The discovery of 
angiostatin, a proteolytic fragment of plasminogen (12), and 
endostatin (13), a proteolytic fragment of collagen XVIII, have 
prompted studies on anti-angiogenic factors. Both angiostatin 
and endostatin have been shown to possess potent anti-
angiogenic and, as a consequence, antitumor activity in several 
animal tumor models (14,15).
It has been shown that a combination of a plasminogen acti-
vator (PA) such as urokinase- and tissue type PA (uPA, tPA), 
and a free sulfhydryl donor (FSD), can adequately generate 
angiostatin in vitro. The plasminogen activator is required for 
the conversion of plasminogen to the active protease plasmin. 
Subsequently plasmin, in the presence of an FSD, excises 
the angiostatin fragment from other plasmin molecules (16). 
We found in a panel of 75 different cell lines derived from 8 
different tumor types, that plasminogen activator expression 
and the ability to generate angiostatin in vitro were clearly 
linked (17). Other reports have shown that several species of 
MMPs (18,19), PSA (20), as well as cathepsin V (21) also play a 
role in angiostatin generation. The fact that several (combina-
tions of) proteases, that each cleave the plasminogen/plasmin 
molecule at a different location, are able to generate angio-
statin, explains the formation of several different angiostatin 
species. The angiostatin species described in the original 
paper by O'Reilly et al (12) consisted of the first 3 kringle 
domains (out of 5) of plasminogen (K1-3), but also K1-4, 
K1-4.5 and K5 species have been reported (22). Although each 
angiostatin species has anti-angiogenic properties (probably 
by inducing apoptosis in vascular cells), the systemic and/or 
site-specific occurrence of these different species, as well as 
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their (relative) contributions to the (anti-)angiogenic balance 
is unclear. In addition, little is known about the mechanisms 
involved in the in vivo generation of angiostatin. Rotenberg 
et al (23) determined the levels of angiostatin, uPA and MMPs 
in ascitic and pleural effusions of 21 cancer patients, and found 
no correlation between the presence of angiostatin and either 
enzyme.
To address this question in a different patient group, we 
collected cyst fluids from benign and malignant ovarian tumors, 
and from functional cysts. In these fluids, we determined the 
presence of plasminogen and angiostatin semiquantitatively by 
western blot analysis, and the corresponding levels of uPA and 
tPA by specific ELISAs. The absence or presence of angio-
statin in the cyst fluids was linked to the levels of plasminogen, 
uPA and tPA.
Materials and methods
Patients. Patients with a cystic ovarian process scheduled for 
surgical treatment were included in the cyst fluid collection 
procedure (n=124). Informed consent was obtained from all 
the patients. We included samples from ovarian carcinoma 
(n=31), borderline tumors (n=17), benign mucinous ovarian 
tumors (n=27), benign serous ovarian tumors (n=28), dermoid 
cysts (n=11) and endometriotic lesions (n=10). After surgical 
removal, the tissue was immediately transported to the 
pathology laboratory where aseptic fine needle aspiration was 
performed to collect cyst fluid samples. Subsequently, cooled 
fluid samples were centrifuged at 3,000 x g for 10 min. The 
supernatant was collected and stored at -35˚C until further 
analyses. Histopathological evaluation was performed by an 
experienced gynecologic pathologist, and clinicopathologic 
characteristics were retrieved from the medical records of 
the patients. For comparison we used follicle fluid collected 
routinely from functional cysts during an IVF procedure from 
24 women.
ELISAs for plasminogen activator components. Determination 
of uPA and tPA concentration was performed by specific 
double determinant ELISAs as described previously (24,25).
Purification of plasminogen and angiostatin. Lysine-sepharose 
slurry (50 µl) prepared according to the manufacturer's 
instructions (Pharmacia, Uppsala, Sweden) was added to 
200 µl of cyst fluid, and incubated overnight on a roller bank 
at 4˚C. Lysine-sepharose was washed twice with phosphate 
buffered saline, and bound material was eluted with 100 µl 
0.2 M ε-amino-capronic acid.
Western blot analyses for plasminogen and angiostatin. 
SDS-PAGE and western blot analyses were performed essen-
tially as described previously (17). Briefly, samples of 15 µl 
purified plasminogen/angiostatin plus 15 µl sample buffer 
were run on a 10% polyacrylamide gel. After electrophoresis, 
samples were electroblotted onto nitrocellulose membranes 
(Schleicher & Schuell, Dassel, Germany). Blots were blocked 
for 60 min in blocking solution [PBS/0.05% Tween-20/2% 
block (Roche, Basel, Switzerland)], followed by overnight 
incubation with polyclonal rabbit anti-human antibody, affinity 
purified against plasminogen kringle domains 1-3, diluted in 
blocking solution. After washing, blots were incubated for two 
hours with peroxidase-conjugated swine anti-rabbit secondary 
antibody (Dako, Glostrup, Denmark). After washing, blots 
were developed by chemiluminescence according to the 
manufacturer's protocol (Roche). Plasminogen and angiostatin 
content were assessed semiquantitatively by visually scoring 
the intensity of the resulting bands as absent (0), low (1), 
moderate (2) or high (3). In addition, the conversion level of 
plasminogen to angiostatin (irrespective of the accompanying 
plasminogen and angiostatin levels) was scored in 5 different 
categories. Category 1 refers to cyst fluids in which no plasmin-
ogen was converted at all, and category 5 to cases of complete 
conversion of plasminogen to angiostatin (in other words no 
remaining plasminogen present). A further three categories of 
partial conversion were defined as: 2, <50% of plasminogen 
converted to angiostatin (plasminogen band more intense); 
3, ~50% of plasminogen converted (bands comparable in 
intensity); and 4, >50% of plasminogen converted (angiostatin 
band more intense).
Statistical analysis. In samples with no conversion of plas-
minogen to angiostatin, the 75% percentile of plasminogen 
activator levels was 7.0 and 18.5 ng/ml for uPA and tPA, 
respectively. We used these values to define an increased level 
of activator components in the analyses. Univariable logistic 
regression was used to study the occurrence of the conversion 
of plasminogen to angiostatin, to the probability of increased 
plasminogen activator component. The dependent variable 
was the probability of increased uPA, increased tPA or an 
increase in both, respectively. The independent variable was 
conversion of plasminogen to angiostatin, in five categories as 
described above. The odds ratios with 95% confidence inter-
vals are presented.
Results
Plasminogen and angiostatin levels in ovarian tumor cyst 
fluid and functional cyst fluid samples. Cyst fluid plasmin-
ogen and angiostatin levels were assessed semiquantitatively 
by western blot analysis. Two examples from each source of 
cyst fluid are shown in Fig. 1. Whereas the molecular weight 
(MW) of the plasminogen we found in the different samples 
appeared to be constant, variations were observed in the 
molecular weights of the different angiostatin species. In 
most samples at least two different angiostatin bands were 
observed. This is particularly clear in sample 1 in Fig. 1, 
showing two bands of ~37 and 42 kDa. In functional cyst 
samples, two angiostatin bands in the 50 kDa range could be 
observed. Next to these rather large differences in molecular 
weight, some more subtle differences were observed as well. 
The angiostatin bands in the two mucinous benign cyst 
fluids, for example (samples 5 and 6 in Fig. 1) are within 
the 37-40 kDa 3 kringle range but have clearly somewhat 
different molecular weights.
A summary of the semiquantitative assessment of the levels 
of plasminogen and angiostatin in each cyst fluid sample is 
shown in Fig. 2 (left panel, plasminogen; middle panel, angio-
statin). High levels of plasminogen were notably found in the 
majority of carcinoma derived samples. In the fluid samples 
derived from other pathological cysts, a large variation in the 
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levels of these proteins was observed. In these types of cyst 
fluids, samples with very large amounts of plasminogen were 
found, next to samples with no plasminogen at all. Compared 
to plasminogen, the observed level of angiostatin was generally 
lower and there were more samples with no angiostatin protein 
at all. The highest percentages of samples with moderate or 
high amounts of angiostatin were derived from carcinoma, 
borderline, and, remarkably, endometriosis cysts.
In contrast to the samples derived from pathological 
cysts, the functional cyst samples all presented with a rather 
consistent pattern of moderate amounts of plasminogen and 
only small amounts (if any) angiostatin. With the exception 
of the instances mentioned above, no further obvious correla-
tions between source of the cyst fluid, and the presence and/or 
quantity of either plasminogen or angiostatin were observed.
In the right panel of Fig. 2, the degree of plasminogen to 
angiostatin conversion is shown, divided in different catego-
ries. Categories were based on the ratio between plasminogen 
and angiostatin content. Category 1 contained those samples 
where sufficient amounts of plasminogen were present with 
no conversion to angiostatin whatsoever. Category 5 contained 
those samples where plasminogen was completely absent 
due to conversion to angiostatin. These two extremes where 
rather uncommon, as in many samples both plasminogen 
as angiostatin was observed, indicating a partial conversion 
of plasminogen to angiostatin. Category 3 contained those 
samples where the levels of plasminogen and angiostatin 
were approximately equal, while in category 2 the conversion 
to angiostatin was low and in category 4 this was high. The 
last category contained samples where both plasminogen and 
angiostatin were not present.
Plasminogen activators in tumor cyst fluid and functional 
cyst fluid samples. As plasminogen activators are in vitro 
Table I. The odds ratio with 95% confidence interval of enhanced conversion of plasminogen to angiostatin for the probability of 
increased uPA, increased tPA and increased either uPA or tPA, respectively, using univariable logistic regression.
 uPA >7.0 tPA >18.5 (uPA >7.0) or (tPA >18.5) ---------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------------
Conversion n OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
level
1 21   1.0 (ref)  1.0 (ref)    1.0 (ref)
2 56   4.0 (1.3-12.3) 0.017 1.2 (0.4-3.8) 0.791   1.9 (0.7-5.3) 0.093
3 29 10.1 (2.7-37.5) 0.001 3.4 (1.0-11.9) 0.052 11.6 (2.6-50.5) 0.022
4 12   3.2 (0.7-14.5) 0.132 4.5 (1.0-20.6) 0.054   6.7 (1.2-38.25) 0.121
5   5   2.1 (0.3-16.6) 0.469 4.8 (0.6-37.4) 0.134   5.3 (0.5-56.2) 0.289
uPA, urokinase type plasminogen activator; tPA, tissue type plasminiogen activator; OR, odds ratio; CI, confidence interval; plg, plasminogen; 
ref, reference.
Figure 1. Western blot analysis of plasminogen and angiostatin content of ovarian tumor cyst and functional cyst fluid samples. The origin of the analyzed cyst 
fluid is shown above each panel; cyst fluid samples derived from 2 different patients per origin are shown. Plasminogen and angiostatin were purified from cyst 
fluid samples by lysine-sepharose chromatography. A rabbit anti-human plasminogen polyclonal antibody was employed to detect plasminogen (92 kDa) and 
angiostatin (between 38 and 50 kDa). MW markers are shown on the left hand side of the panels. Beneath the panels, the semiquantitative scoring, as described 
in Materials and methods, of plasminogen levels, angiostatin levels and the degree of plasminogen to angiostatin conversion is shown.
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potent mediators of plasminogen to angiostatin conversion, we 
assessed uPA and tPA levels in the cyst fluid samples to study 
whether the same mechanism is involved in in vivo angiostatin 
generation. In Fig. 3, uPA (left panel) and tPA levels (right 
panel) in the different types of cyst fluid are shown. All cyst 
fluid groups with the exception of endometriosis (see below) 
contained a number of samples with no detectable uPA. 
Median uPA levels tended to be lower in benign lesions. A 
notable exception was the endometriosis samples, that all 
contained uPA, some to a very high level. In fact, the mean 
uPA level in this group was by far the highest and significantly 
different from all other groups (one-way ANOVA, p<0.001). 
This pattern was not observed for tPA, as this enzyme showed 
highest median levels in serous benign tumors cyst fluid, 
followed by borderline tumors and endometriosis. Both uPA 
and tPA were low in dermoid tumors and functional cysts. 
The tPA levels in the endometriosis group were not strikingly 
different from the other cyst fluid groups.
Plasminogen activator levels are associated with the conver-
sion of plasminogen to angiostatin. Fig. 4 shows the levels 
of uPA (left panel) and tPA (right panel) in relation to the 
conversion level of plasminogen to angiostatin. Samples that 
contained neither plasminogen nor angiostatin were excluded 
from this plot, as these are not informative.
Mean uPA levels were clearly lowest in the samples in 
which no conversion of plasminogen to angiostatin occurred 
(category 1). In samples with a low to moderate levels of 
conversion (categories 2 and 3), uPA levels were signifi-
cantly higher (t-test, p=0.046 and 0.003, respectively). With 
increasing levels of plasminogen to angiostatin conversion 
(category 4), the mean uPA declined again. Remarkably, in 
the small group (n=5) of samples with a complete conversion 
of plasminogen to angiostatin, uPA levels were comparable to 
those in the group of samples with no conversion at all.
The differences in tPA content between the categories 
with different levels of plasminogen to angiostatin conversion 
were less obvious and not significantly different, although the 
median tPA level increased with increasing conversion levels.
As it is possible that both uPA and tPA are involved in 
angiostatin generation, and that insufficient levels of one 
enzyme are compensated for by a sufficient level of the other, 
we also plotted uPA against tPA concentration for each group 
of plasminogen to angiostatin conversion (Fig. 5). As in Fig. 4, 
samples that contained neither plasminogen nor angiostatin 
were left out of the plot. In 12 of the 21 fluid samples in which 
no conversion occurred (category 1; Fig. 5 left panel), uPA as 
well as tPA was <75% percentile in this group. In 4 samples, 
only the tPA concentration (≤78 ng/ml) was increased, while in 
another 4 only the uPA concentration was increased (≤16.2 ng/
ml). In one sample, both tPA and uPA plasminogen activators 
(40 and 22 ng/ml, respectively) were increased. Apparently, 
the presence of plasminogen and uPA and/or tPA is not always 
sufficient to convert plasminogen to angiostatin.
In categories 2-5 samples, where at least some degree of 
plasminogen to angiostatin conversion was observed (Fig. 5 
right panel), ~40% of samples with a low conversion level (cate-
gory 2) also showed low uPA and tPA levels (below dotted lines; 
lower left quadrant of Fig. 5 right panel). Twenty-three percent 
of category 2 samples, however, presented with high uPA and 
tPA levels (upper right quadrant), again indicating that the 
combination of plasminogen and a plasminogen activator is not 
always sufficient for angiostatin generation. Samples displaying 
an intermediate, high or complete conversion of plasminogen to 
angiostatin (categories 3-5), were found predominantly in the 
upper quadrants, indicating high uPA and/or tPA levels. The 
probability of increased uPA and/or tPA levels given a certain 
conversion level is given in Table I. A considerable amount of 
samples was found in the upper left quadrant (only high tPA 
levels, 22%) or lower right quadrant (only high uPA levels, 
33%). Interestingly, a small minority (five samples, including 
one with a complete conversion of plasminogen to angiostatin) 
was positioned in the lower left quadrant, suggesting that in 
these samples neither uPA nor tPA was involved in angiostatin 
Figure 2. Summary of plasminogen levels (left panel), angiostatin levels (middle panel), both varying from absent (0, white) to high (3, black) and the degree of 
plasminogen to angiostatin conversion (right panel, on a scale from 1, little conversion, to 5, complete conversion) in different types of cyst fluids. The number 
of samples per group is given on the right side of the figure. Levels and degree of conversion were scored semiquantitatively as described in Materials and 
methods.
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Figure 3. uPA (left panel) and tPA (right panel) levels in different types of cyst fluids. Median levels are shown as horizontal bars.
Figure 4. Degree of plasminogen to angiostatin conversion, plotted against uPA (left panel) and tPA (right panel) concentration. Horizontal bars represent mean 
levels. Dotted lines represent the 75% percentile of uPA or tPA in category 1 (samples without conversion of plasminogen to angiostatin).
Figure 5. Degree of plasminogen to angiostatin conversion plotted against uPA as well as tPA concentration. Left panel, no conversion of plasminogen to 
angiostatin. Right panel, different levels of plasminogen to angiostatin conversion. Dotted lines represent the 75% percentiles of uPA and tPA in category 1 
(samples without conversion of plasminogen to angiostatin).
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generation. When analyzing our data for each source of cyst 
fluid separately, we did not find any tumor-specific angiostatin 
generating pathways (data not shown).
Discussion
Angiogenesis is a prerequisite for (pathological) tissue growth 
and the formation of metastatic or ectopic tissue. Angiogenesis 
is the net result of the balance between of pro- and anti-
angiogenic molecules. Angiostatin, a proteolytic fragment of 
plasminogen with potent anti-angiogenic properties, has been 
extensively studied with regard to the molecules involved in 
excising the different angiostatin fragments from its parent 
molecule. Circulating angiostatin has been demonstrated in 
tumor-bearing as well as control mice, and also in human 
cancer patients and healthy subjects.
In our angiostatin containing samples we usually observed 
at least two angiostatin bands, that differed ~ 4 kDa in molec-
ular weight. These tandem bands were either found in the 
37-40 kDa range, or in the 48-52 kDa range. As the molecular 
weight of one plasminogen kringle domain is ~12 kDa, the 
two sets of tandem bands may represent angiostatin species 
containing 3 or 4 kringle domains, respectively. As reported 
previously, both the 3 kringle and 4 kringle angiostatin species 
possess anti-angiogenic properties. We also observed angio-
statin species in the 37-40 kDa range that were only slightly 
(1-2 kDa, or even less) different from each other with regard 
to their molecular weight. Whether these bands represent 
different glycosylation forms of the same proteolytic frag-
ment, or proteolytic fragments of different sizes, is unknown. 
Interestingly, the angiostatin species with a molecular weight 
between 48 and 52 kDa were observed exclusively in the func-
tional cyst samples, whereas the 37-40 kDa species were only 
found in the pathological samples. This finding suggests that 
angiostatin generation is different under physiological condi-
tions compared to pathological conditions. We could, however, 
not detect any differences between the levels of uPA or tPA 
on one hand, and the molecular weight form of the angiostatin 
that was generated on the other.
Thus far, the mechanisms involved in physiological as well 
as pathological angiostatin generation in vivo, have not been 
elucidated. Rotenberg et al (23) have studied angiostatin levels 
in blood, and in ascitic and pleural effusions from 21 patients 
with malignant disease. No link between angiostatin levels, and 
concentrations of either MMPs or plasminogen activators could 
be established. Murthi et al (26) analyzed plasminogen levels 
and uPA activity in tissue extracts and in the urine of patients 
with normal, benign, borderline, and invasive serous tumors 
and suggested that proteolytic activity of the plasminogen acti-
vation cascade increases in serous epithelial ovarian carcinoma 
in combination with a decrease in plasminogen and angiostatin 
levels. Drenberg et al (27) assayed angiostatin levels in plasma 
and urine by ELISA in normal samples, benign gynecological 
disease, primary peritoneal cancer and epithelial ovarian 
cancer. Angiostatin was elevated in urine of ovarian cancer 
patients regardless of tumor grade, stage, size, histological 
subtype, creatinine levels, menopausal status, or patient age.
In our study, we show a clear correlation between the 
concentration of uPA, and angiostatin content in cyst fluids 
derived from malignant and benign ovarian disease, endometri-
otic lesions, and functional cysts. We also identified, however, 
a number of samples containing angiostatin but no uPA or tPA, 
and, on the other hand, plasminogen containing samples with 
substantial levels of uPA, tPA or both, but no angiostatin. In the 
first group of samples other proteases, for instance members 
from the MMP family may have been involved in excising the 
angiostatin moiety from the plasminogen parent molecule. In 
the second group of samples, molecules such as plasminogen 
activator inhibitor-1 (PAI-1) may have modulated the enzy-
matic activity of the plasminogen activator, thus preventing 
angiostatin generation.
Our data are in accordance with a previous report in which 
we analyzed the angiostatin generating capacity of a large 
number of tumor cell lines (17). In this study we found a strong 
correlation between uPA and tPA production and angiostatin 
generation, but we also observed angiostatin generation by a 
number of uPA/tPA negative cell lines.
Our results may explain the dual role that plasminogen 
activators appear to play in tumor progression. These proteases 
have been described to be positively- as well as negatively- 
correlated with the degree of malignancy of several tumor 
types, e.g., breast cancer (28-32). The role of plasminogen 
activators in in vivo angiostatin generation may lead to a shift 
in the angiogenic balance towards the inhibitory side, resulting 
in a less malignant tumor and, consequently, in a negative 
correlation between plasminogen activator expression and 
tumor malignancy and/or progression.
Using angiostatin as a (potential) treatment, is hampered by 
problems producing sufficient amounts of active angiostatin, 
and subsequent effective administration of the compound. 
In parallel studies (33,34) we have attempted to bypass these 
problems by trying to stimulate the endogenous in vivo angio-
statin production. In a human melanoma xenograft model, 
administration of a combination of tPA and a free sulfhydryl 
donor to tumor bearing mice resulted in increased levels of 
circulating angiostatin, and in an inhibition of tumor growth. 
Further elucidation of the mechanism(s) involved in in vivo 
angiostatin production, may eventually lead to the develop-
ment of alternative anti-angiogenic therapeutic approaches 
aimed at increasing the circulating levels of angiostatin.
In conclusion, our data show that plasminogen activators 
are clearly involved in angiostatin formation in vivo in ovarian 
cysts. Most likely, however, other proteases, as well as inhibi-
tors of plasminogen activators, are involved as well.
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